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Abstract
Introduction: The neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) is considered to be a
potential therapeutic agent for prevention of cerebral ischemia. Ischemia is a most common cause of death after
heart attack and cancer causing major negative social and economic consequences. This study was designed to
investigate the effect of PACAP38 injection intracerebroventrically in a mouse model of permanent middle cerebral
artery occlusion (PMCAO) along with corresponding SHAM control that used 0.9% saline injection.
Methods: Ischemic and non-ischemic brain tissues were sampled at 6 and 24 hours post-treatment. Following
behavioral analyses to confirm whether the ischemia has occurred, we investigated the genome-wide changes in
gene and protein expression using DNA microarray chip (4x44K, Agilent) and two-dimensional gel electrophoresis
(2-DGE) coupled with matrix assisted laser desorption/ionization-time of flight-mass spectrometry (MALDI-TOF-MS),
respectively. Western blotting and immunofluorescent staining were also used to further examine the identified
protein factor.
Results: Our results revealed numerous changes in the transcriptome of ischemic hemisphere (ipsilateral) treated
with PACAP38 compared to the saline-injected SHAM control hemisphere (contralateral). Previously known
(such as the interleukin family) and novel (Gabra6, Crtam) genes were identified under PACAP influence. In parallel,
2-DGE analysis revealed a highly expressed protein spot in the ischemic hemisphere that was identified as
dihydropyrimidinase-related protein 2 (DPYL2). The DPYL2, also known as Crmp2, is a marker for the axonal growth
and nerve development. Interestingly, PACAP treatment slightly increased its abundance (by 2-DGE and
immunostaining) at 6 h but not at 24 h in the ischemic hemisphere, suggesting PACAP activates neuronal defense
mechanism early on.
Conclusions: This study provides a detailed inventory of PACAP influenced gene expressions and protein targets in
mice ischemic brain, and suggests new targets for thereaupetic interventions.
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Introduction
In 1989, a new hypothalamic hormone with the significant
ability to activate adenylate cyclase in rat pituitary cell cul-
tures was discovered and aptly named pituitary adenylate
cyclase-activating polypeptide or PACAP [1,2]. As reported
in those first papers, PACAP exists in two amidated forms,
PACAP38 and its truncated form, PACAP27. The ovine
PACAP38 is 176 amino acids long, proceeded by a putative
signal peptide and a proregion (107 amino acids), and
followed by a Gly-Arg-Arg sequence for proteolytic pro-
cessing and C-terminal amidation; the human PACAP38
has been shown to be identical to the isolated ovine
PACAP [3]. The sequence of PACAP38 encompasses an
internal cleavage-amidation site (Gly28-Lys29-Arg30),
suggesting that it can generate a 27 residue-amidated
polypeptide fragment or PACAP27. Similarly, the rat
(PACAP precursor that is highly similar to the ovine and
human PACAP precursors) and the mouse (PACAP pre-
cursor shows 81 to 93% sequence similarity) PACAP
cDNAs were cloned (reviewed in [4]).
To briefly note some characteristics, PACAP is a
member of the secretin, glucagon, and vasoactive in-
testinal polypeptide (VIP) family showing the most
homology to VIP; all peptides are present in the tissue
but PACAP38 is the most dominant form [5]. An import-
ant finding was on the potency of adenylate cyclase acti-
vation by PACAP 1,000 to 10,000 times greater than VIP,
as demonstrated in pituitary cell, neuron, and astrocyte
cultures. PACAP and its receptors (PAC1, VPAC1, and
VPAC2) are widely distributed in the brain (central
nervous system, CNS) and peripheral organs (notably
endocrine pancreas, gonads, respiratory, and urogenital
tracts). Consequently, PACAP exerts pleiotropic effects
including control of neurotransmitter release, vasodila-
tion, bronchodilation, activation of intestinal motility, in-
crease in insulin and histamine secretion, immune
modulation, and stimulation of cell proliferation and/or
differentiation. These and other characteristics and
functions of PACAP are comprehensively reviewed by
Arimura [4] and Vaudry et al. [6].
PACAP is now considered a potent neurotrophic and
neuroprotective peptide [7-11]. The specific role of
PACAP in neuroprotection is of interest to our study,
and forms the basis for the present experiments with an
aim to unravel new potential targets of PACAP at the
gene and/or protein level, and possible mechanisms
involved therein. PACAP exerts potent neuroprotective
effects not only in vitro but also in in vivo models of
Parkinson's disease, Huntington's disease, traumatic
brain injury, and stroke. The neuroprotective effects of
PACAP are based on its capacity to prevent neuronal
apoptosis by acting directly on neurons or indirectly
through the release of neuroprotective factors by astro-
cytes [12,13]. These biological activities are mainly
mediated through activation of the PAC1 receptor which
is currently considered a potential target for the treat-
ment of neurodegenerative diseases. However, the use of
native PACAP, the endogenous ligand of PAC1, as an ef-
ficient neuroprotective drug is actually limited by its
rapid degradation. Moreover, injection of PACAP in
humans induces peripheral side effects that are mainly
mediated through VPAC1 and VPAC2 receptors [7].
The intraventricular infusion of PACAP38 at 1 pmol/h
significantly delayed neuronal cell death in the hippo-
campal CA1 region that would normally occur a couple
of days after induction of ischemia. The intravenous ad-
ministration of PACAP (only 16 pmol/h) decreased
delayed neuronal cell death in the hippocampus. Subse-
quently, another study showed that PACAP quickly
crosses the blood–brain barrier at approximately 0.12%
by a saturable system. PACAP prevented delayed neur-
onal cell death even when it was given intravenously 24
h after ischemia induction. Moreover, anti-apoptotic fac-
tors and anti-cell-death pathways were increased by
PACAP and decreased by the addition of the PAC1R an-
tagonist, PACAP 6–38, after ischemia and in other
in vitro studies. The studies suggest that the neuropro-
tection by PACAP depends on the activation of the
PAC1R, and exogenous PACAP might extend the thera-
peutic time window for treatment of ischemia-related
conditions, such as stroke [10].
In an effort to unravel PACAP molecular targets in
the brain, especially under ischemia, we further
advanced our research using the established permanent
middle cerebral artery occlusion (hereafter referred to
as PMCAO) model mice and the optimized DNA
microarray approach with the 44K mouse whole gen-
ome chip [14]. Our study employed the intraluminal
filament technique PMCAO model because of its sim-
plicity and noninvasive characteristics compared to the
classical electrocoagulation method for PMCAO. The
transient MCAO results in reperfusion injury, and to
avoid this complication, the method of choice was in
favor of intraluminal PMCAO. Further, we also applied
the proteomics approach [15,16] to examine the protein
changes in the same sample/brain hemisphere as was
used for the transcriptomics study.
We used DNA microarray analysis to answer two ques-
tions. 1) What are the PACAP influenced genes? 2) Can
we pinpoint the transcripts specifically altered (increased
or decreased) by PACAP, that is, the genes that are not
the result of ischemia itself, and are predominantly regu-
lated by PACAP? By proteomics, we aimed to identify
proteins from the two-dimensional gel profile that was
differentially regulated by PACAP under the ischemic
condition. Our results reveal numerous potential gene
candidates, such as interleukin family members, Gabra6,
and Crtam that might be involved in PACAP-mediated
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neuroprotective mechanisms. The identification of an
important protein involved in neuronal function, the col-
lapsin response mediator protein (CRMP2) [17], was an-
other key finding of a PACAP-regulated protein in the
ischemic hemisphere. Results presented show the useful-
ness of omics approaches in screening of potential targets
of PACAP-regulated genes and proteins.
Methods
Animals and husbandry
Animal care and experimental procedures were used as
approved by the Institutional Animal Care and Use
Committee of Showa University (School of Medicine),
Tokyo, Japan. Thirty male mice (C57BL/6J), 9-weeks-
old, body weight 25 to 35 g, were purchased from
Charles River (Kanagawa, Japan). Mice were housed at
the Animal Institution in Showa University in acrylic
cages (eight mice/cage) maintained at 23°C with a standard
12-h light/dark cycle, optimum humidity, and temperature
control. Animals were given access to tap water and
laboratory chow ad libitum.
Permanent middle cerebral artery occlusion (PMCAO),
PACAP treatment, and SHAM control
The experimental design is presented in Figure 1. The
PMCAO-model mice were generated as described pre-
viously [14]. Briefly, the mice were anesthetized with
4% sevoflurane (induction) and 2% sevoflurane (main-
tenance) in a 30% O2 and 70% N2O gas mixture via a
face mask. An incision was then made in the cervical
skin followed by opening of the salivary gland, and the
right common carotid artery was visualized. A midline
cervical incision was made to expose the external ca-
rotid artery. The intraluminal filament technique was
used, as reported by Hori et al. [14] to generate the
PMCAO model. The PACAP38 (1 μL containing 1 pmol)
or 1 μL of saline (0.9% NaCl) was injected intracerebro-
ventrically, immediately after PMCAO. PACAP38
(Peptide Institute Inc., Osaka, Japan; supplier temperature
was −20°C) was dissolved at 10-5M concentration by
saline, and stored at −80°C. PACAP test solution (for
injection) was diluted × 10 times with 0.9% NaCl just
before use. In the sham control animals, the wound
was sutured following exposure of the external carotid
artery. The PACAP38 or saline was injected intracereb-
roventrically in the same concentrations as above. After
injection, the animals were returned to their cages. A
total of eight groups were prepared: four groups of
three, seven, four and five mice in the PMCAO plus
PACAP38 and PMCAO plus saline cohorts at 6 and
24 h after the operation, respectively, and five mice
each in the control (sham) plus PACAP and saline
groups at 6 and 24 h after operation, respectively (see
Additional file 1: Table S1). We used three mice each
in PMCAO groups that exhibited neurological grades
G1 and G2 [13,14], and three mice each at random in
sham groups for the subsequent downstream analysis.
Some of the mice were examined for ischemia by TTC
(2, 3, 5-triphenyltetrazolium chloride) staining of brain
sections (2-mm slices) at 37°C for 10 minutes [13,14,18].
Dissection of brain, sampling and storage, extraction of
total RNA, cDNA synthesis, and semiquantitative RT-PCR
Six or 24 hours post-injection of PACAP38 or saline, the
mice were removed from their cages, decapitated, and
their brains carefully removed on ice. The left (contralat-
eral) and right (ipsilateral; ischemic) hemispheres were
dissected and placed in 2-mL Eppendorf tubes, which
were then quickly immersed in liquid nitrogen before
being stored at −80°C prior to further analysis (Figure 1).
Stored tissues were ground to a very fine powder with
liquid nitrogen, and used for total RNA extraction, fol-
lowed by a quantity and quality check [14-16]. To validate
the total RNA quality and subsequently synthesized
cDNA, RT-PCR was carried out using two commonly
used housekeeping genes glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) and beta-actin as positive
controls [14,19]. The 3’-UTR gene-specific primers were
designed (see Additional file 2: Table S2). The cDNA
synthesis and RT-PCR analysis protocol used is as follows:
Total RNA samples were first DNase-treated with RNase-
free DNase (Stratagene, Agilent Technologies, La Jolla,
CA, USA). First-strand cDNA was then synthesized in a
20 μL reaction mixture with an AffinityScript QPCR
cDNA Synthesis Kit (Stratagene) according to the proto-
col provided by the manufacturer, using 1 μg total RNA.
The reaction conditions were: 25°C for 5 minutes, 42°C
for 5 minutes, 55°C for 40 minutes and 95°C for 5 min-
utes. The synthesized cDNA was made up to a volume of
50 μL with sterile water supplied in the kit. The reaction
mixture contained 0.6 μL of the first-strand cDNA, 7
pmol of each primer set and 6.0 μL of the Emerald Amp
PCR Master Mix (2X premix) (TaKaRa Shuzo, Shiga,
Japan) in a total volume of 12 μL. Thermal-cycling (Ap-
plied Biosystems, Tokyo, Japan) parameters were as fol-
lows: after an initial denaturation at 97°C for 5 minutes,
samples were subjected to a cycling regime of 20 to 40
cycles at 95°C for 45 s, 55°C for 45 s, and 72°C for 1 mi-
nute. At the end of the final cycle, an additional extension
step was carried out for 10 minutes at 72°C. After comple-
tion of the PCR the total reaction mixture was spun down
and mixed (3 μL), before being loaded into the wells of a
1.2/1.8% agarose fine powder (catalogue number 02468–
95, Nacalai Tesque, Kyoto, Japan) gel. Electrophoresis was
then performed for approximately 22 minutes at 100 Volts
in 1X TAE buffer using a Mupid-ex electrophoresis sys-
tem (ADVANCE, Tokyo, Japan). The gels were stained (8
μL of 10 mg/mL ethidium bromide in 200 mL 1X TAE
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Figure 1 (See legend on next page.)
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buffer) for approximately 7 minutes and the stained bands
were visualized with the ChemiDoc XRS+ imaging system
(Bio-Rad, 6000 Alfred Nobel Drive, Hercules, CA 94547,
USA).
DNA microarray analysis in the ipsilateral (right)
hemisphere
A mouse 4 × 44K whole genome oligo DNA microarray
chip (G4122F, Agilent Technologies, Palo Alto, CA,
USA) was used for global gene expression analysis using
the ipsilateral (ischemic) hemisphere. Briefly, total RNA
(900 ng; 300 ng for each replicate pooled) was labeled
with either Cy3 or Cy5 dye using an Agilent Low RNA
Input Fluorescent Linear Amplification Kit (Agilent).
Fluorescent-labeled targets of control (sham) as well as
treated (PMCAO) samples with PACAP38 or without
PACAP38 (saline) were hybridized to the same micro-
array slide with 60-mer probes. As illustrated in Figure 1,
in this experiment we compared the PMCAO plus
PACAP38-injected mice to PMCAO plus saline, that is,
the ipsilateral brain region of the PMCAO mice was
compared with the same right hemisphere of the control
mice. Similarly, sham control plus PACAP38-injected
mice to sham control plus saline were analyzed to iden-
tify only the PACAP38-influenced genes. A flip labeling
(dye-swap or reverse labeling with Cy3 and Cy5 dyes)
procedure was followed to nullify the dye bias associated
with unequal incorporation of the two Cy dyes into
cDNA [14,20]; and references therein].
Briefly, the same total RNA (900 ng) samples were
labeled twice with Cy3 or Cy5: a Cy5-labeled treatment
(TCy5) and a Cy3-labeled control (CCy3) was hybridized
on a slide and then a Cy3-labeled treatment (TCy3) and
a Cy5-labeled control (CCy5) were reversely hybridized
on another to revise the dye bias associated with unequal
incorporation of two Cy dyes into cRNA. Hybridization
and wash processes were performed according to the
manufacturer’s instructions, and hybridized microarrays
were scanned using an Agilent Microarray scanner
G2565BA. For the detection of significantly differentially
expressed genes between control and treated samples,
each slide image was processed by Agilent Feature Ex-
traction software (version 9.5.3.1). Signal ratios of each
spot on all slides were normalized by the software and fi-
nally, the log ratio of each spot for technical replicates
was averaged to give a representative value for each
pooled sample and to adjust remaining gene-specific dye
bias. The output of microarray analysis used in this study
are available under the series number GSE 37565, at the
NCBI Gene Expression Omnibus (GEO) public functional
genomics data repository (http://www.ncbi.nlm.nih.gov/
geo/info/linking.html). To validate the microarray data
(ipsilateral hemisphere) RT-PCR, as described above, was
also performed on randomly up- and down-regulated
genes using 3’-UTR specific gene primers (see Additional
file 2: Table S2).
Extraction of total soluble protein
Total protein was extracted from sample powders
(around 50 mg) of the contralateral and ipsilateral hemi-
spheres (control and treatment) using a previously used
lysis buffer containing thiourea and Tris (LB-TT) for ex-
traction of brain proteins [15,16]. The composition of
slightly modified LB-TT was as follows: 7 M (w/v) urea,
42 g; 2 M (w/v) thiourea, 15.2 g; 4% (w/v) CHAPS, 4.0 g;
18 mM (w/v) Tris–HCl (pH 8.0), 1.8 mL; 14 mM (w/v)
Trizma base, 169.5 mg; 0.2% (v/v) Triton X-100, 0.2 mL;
50 mM (w/v) DTT, 771.5 mg; 1% (v/v) pH 3–10 Ampho-
lyte, 1 mL; and two EDTA-free proteinase inhibitor
(Roche Diagnostics GmbH, Mannheim, Germany)
tablets in a total volume of 100 mL; see Additional file 3:
Figure S1 for preparation of LB-TT at room temperature
(RT). To extract protein, 1 mL of LB-TT was quickly
added to the 2-mL microfuge tube containing the sam-
ple powder (immediately after removal from the −80°C
deep freezer) and immediately mixed by vortexing (at
full speed using a Lab mixer, Iwaki, Tokyo, Japan) for 1
minute at RT. The protein solution in LB-TT was incu-
bated at RT for 30 minutes with mixing by vortexing
(for 30 sec) and sonication (for 30 sec in a water bath-
type sonicator) for a total of five times. The insoluble
protein pellet and/or debris were pelleted by centrifuga-
tion at 18,500 g for 15 minutes at 20°C in a high-speed
refrigerated micro centrifuge (MX-150, TOMY, Tokyo,
Japan). The clear supernatant (around 900 μL) was
transferred to a new 1.5-mL microfuge tube, and stored
at −80°C as the total soluble protein. Prior to storage, a
0.2 mL aliquot of total protein solution was transferred
to a new 2-mL microfuge tube and processed for a sec-
ond purification, clean up, and concentration step, using
the ProteoExtract Protein Precipitation Kit (Calbiochem,
Darmstadt, Germany; catalague number 539180). This
additional step (see Additional file 4: Figure S2) removes
any impurities while concentrating the protein. The
(See figure on previous page.)
Figure 1 The experimental outline and workflow. Effect of intracerebroventricular administration of pituitary adenylate cyclase-activating
polypeptide (PACAP)-38 into the ischemic mouse brain (permanent middle cerebral artery occlusion, PMCAO model) is evaluated at the
molecular level in the ipsilateral (right) hemisphere. Sham control treated with saline is used for the comparison. TTC staining shows he ischemic
region in the brain. The ipsilateral hemisphere is sampled and finely powdered in liquid nitrogen, followed by investigation into molecular level
changes at the level of gene and protein expressions by DNA microarray and proteomics approaches, respectively.
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pelleted protein, visible as a white solid precipitate at the
bottom of the tube, was re-suspended in LB-TT (around
0.2 mL) as above. Protein concentration was determined
with a Coomassie PlusTM Protein Assay Kit (PIERCE,
Rockford, IL, USA) using bovine serum albumin (BSA)
as a standard and a NanoDrop 2000 spectrophotometer
(Thermo Scientific, Wilmington, DE, USA).
Two-dimensional gel electrophoresis and visualization of
the separated proteins
The first-dimension separation was carried out using pre-
cast IPG strip (pH 4 to 7, 18 cm; GE Healthcare Bio-
Sciences AB, Uppsala, Sweden) gels on a CoolPhoreStar
IPG-IEF Type-PX unit (Anatech, Tokyo, Japan) followed
by the second dimension using hand-cast polyacrylamide
gels on an Anatech CoolPhoreStar SDS-PAGE Dual-200
K unit (Anatech, Tokyo, Japan). Two-dimensional gel
electrophoresis was performed as essentially described by
Toda and Kimura [21]. The detailed protocol for the first-
and second dimension-run is described in Additional file
5: Figure S3. After two-dimensional gel electrophoresis,
the separated proteins were visualized by staining with
Flamingo fluorescent gel stain (catalogue number 161–
0491, Bio-Rad). Briefly, the gel was fixed in 200 mL (two-
dimensional gel) of fixing solution (40% methanol and
10% acetic acid in MQ water) for 30 minutes at RT,
followed by staining with 1X diluted (in MQ water)
Flamingo stain (stock of 10X) for 1 h in the dark. The
stained proteins were visualized after washing three
times for 1 minute each in MQ water with a Fluoro-
PhoreStar 3000 image analysis system (Anatech). The
gel images were saved as 8-bit TIFF files for further
analysis.
Protein identification by matrix-assisted laser
desorption/ionization-time of flight-mass spectrometry
(MALDI-TOF-MS)
Protein spot was excised from the gel using a gel picker
(1.8 mm diameter) in combination with a robotic spot
analyzer (FluoroPhoreStar 3000, Anatech) and placed in
a sterile 0.5 mL microfuge tube (Safe-lock tubes, Eppendorf
AG, Hamburg, Germany). Excised protein spots can be
stored at 4°C till further analysis. For enzymatic digestion
prior to mass spectrometry (MS) analysis 100 μL of 50 mM
ammonium bicarbonate (NH4HCO3) (w/v) solution in 50%
acetonitrile (ACN) (v/v) was added to the excised spot in
the tube, and rinsed for 10 minutes under constant shak-
ing in a tube shaker at RT. Following spin-down of the
washed gel piece, the NH4HCO3-ACN solution was
removed and the gel was vacuum-dried for 30 minutes
(Centrifugal vacuum/SpeedVAc evaporator, Eyela, Tokyo,
Japan) at RT. To the dried gel pieces, 2 μl of trypsin solu-
tion (10 mM NH4HCO3 and 10 ng/μL of trypsin) was
added, and the microfuge tube was kept on ice for 30
minutes, followed by incubation at 37°C for 4 h to over-
night for digestion of the protein in gel. Tryptic peptides
were extracted with 10 μL of 75% ACN containing
0.025% trifluoroacetic acid (TFA) (v/v) for 15 minutes by
ultrasonication (water bath-type). Following a spin-down
of any gel debris, the supernatant was analyzed by MS.
The supernatant can also be stored at −40°C/-80°C for
long-term (1 year) storage.
For MALDI-TOF-MS analysis, we first prepared the
matrix solution by dissolving α-Cyano-4-hydroxycin-
namic acid (4-CHCA, Shimadzu Biotech, Kyoto, Japan)
in 1:1 100% ACN and 0.1% TFA (5 mg of 4-CHCA is
dissolved in 500 μL of ACN-TFA solution to give 10 μg/
μL 4-CHCA. We next loaded 0.5 μL of the above matrix
mixture onto any numbered spot area on the stainless
steel MALDI sample plate and left to dry for 5 minutes
at RT followed by addition of 1 μL of the peptide sample
solution to the same spot, dried for a further 10 to 15
minutes. The ready sample plate was inserted into the
vacuum slot of the AXIMA Performance MALDI-TOF-
MS (Shimadzu Biotech, Kyoto, Japan) and peptides were
identified by Peptide Mass Fingerprint (PMF) analysis.
The parent ion masses were measured in the reflectron
mode with an accelerating voltage of 24.4 kV. A two-
point internal standard for calibration was used with an
angiotensin 2 (human, A9525, Sigma; m/z 1046.54 Da)
and ACTH fragment 18–39 (human, A0673, Sigma; m/z
2465.20 Da). Peptides were selected in the mass range of
900 to 5,000 Da. For data processing, we used MASCOT
program (http://www.matrixscience.com). Searching
conditions/parameters were fixed (Carbamidomethyl, C)
and variable modifications (methionine, M), mass values
(monoisotopic), peptide mass (unrestricted), peptide
mass tolerance (± 0.3 Da), peptide charge state (1+), and
maximum mixed cleavage (1). NCBInr [20120113
(16852130 sequences; 5788275850 residues) (Taxonomy,
Mus musculus (house mouse) 144612 sequences)] and
SWISSPROT [2012_12 (533657 sequences; 189261966
residues) (Taxonomy, Mus musculus (house mouse)
16415 sequences)] databases were used.
Western blot analysis
The separated proteins after SDS-PAGE (mini-gel;
Additional file 6: Figure S4) were transferred onto a
polyvinyldifluoride (PVDF) (Trans-Blot Turbo Midi
PVDF, 0.2 μM, Transfer Packs kit; catalogue number
170–4157). The Trans-Blot Turbo Transfer System (Bio-
Rad) was used for the electrotransfer (StandardSD proto-
col; 25V, 1.0 A, 30 minutes). Following the transfer of pro-
teins on the PVDF membrane (and also confirmed by
visualizing all the 10 colored molecular mass standards), it
was incubated in 25 mL of 5% blocking solution (Block-
Ace powder, catalogue number UK-B80, DS Pharma,
Osaka, Japan; Yukizurishi, Sapporo, Hokkaido, Japan) for
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1 h under constant slow shaking at RT. Blocking solution
was prepared by dissolving 4 g powder in 80 mL 1X TTBS
[10X TTBS: NaCl, 80 g; 1M Tris–HCl, pH 7.5, 200 mL;
Tween-20, 5 mL]. Western blotting and detection was car-
ried out using the Immun-Star WesternC Chemilu-
minescent Kit (catalogue number 170–5070, Bio-Rad)
following the manufacturer’s instructions. Blocking solu-
tion was decanted and the membrane was washed once
in 1X TTBS (5 minutes), followed by incubation in 25
mL of primary antibody solution (PAS) (1 μL rabbit anti-
CRMP2 protein antibody; catalogue number ab62661;
100 μg, 2 mg/mL; Abcam, www.abcam.co.jp) for 1 h, as
above. The membrane was then washed with 25 mL of
1X TTBS for five times. After decanting the last TTBS
wash, the membrane was incubated in 25 mL of second-
ary antibody solution (SAS; 0.5 μL of Amersham, ECL
anti-rabbit IgG, HRP linked species-specific whole anti-
body (from Donkey); catalogue number NA 934; GE
Healthcare) for 1 h, with slow shaking at RT. The 1X
TTBS wash step was repeated five times. For blot devel-
opment, the luminol/enhancer and peroxide buffer solu-
tions were mixed in a 1:1 ratio (1 mL:1 mL; one
membrane volume) and spread over the membrane and
incubated at RT for 5 minutes. Excess solution was
drained by touching one end of the membrane on a Kim-
Wipe paper towel, and the signal (cross-reacting protein
bands) was visualized by x-ray film (Kodak, Tokyo, Japan)
and on a ChemiDoc XRS+ imaging system. The western
blot analysis was repeated at least three times, and repre-
sentative data from the image obtained using an X-ray
film is shown.
Immunofluorescent staining
The brains were removed and immersed for 1 day in 0.1
M phosphate buffer (PB, pH 7.2) containing 2% parafor-
maldehyde and then for 2 days in 0.1 M PB containing
20% sucrose, at −80°C (see Additional file 7: Figure S5)
[22,23]. The brains were then embedded in the mixture
of 20% sucrose in 0.1 M PB and Tissue Tek Optical Cut-
ting Temperature (OCT) solution (2:1; Miles Inc.,
Elkhart, IN, USA), frozen on dry ice, and stored at −80°C
until required. Sections, 8 μm thick, were subsequently
cut with a cryostat (HYRAX C50, Microedge Instru-
ments, Tokyo, Japan), and mounted onto gelatin-coated
glass slides. Immunofluorescent staining was carried out
as described previously [23,24]. Prior to detection of the
desired protein, the 8-μm frozen sections were immersed
in 0.01 M PBS solution and washed for three times 5
minutes each wash, followed by blocking in 5% normal
horse serum (in 0.01 M PBS). Sections were incubated
overnight at 4°C in mixtures of primary antibodies, con-
sisting of rabbit anti-CRMP2 antibody (1:2000) with
mouse anti-NeuN antibody (1:400) for neuronal cell mar-
ker. Post-incubation, the sections were washed with 0.01
M PBS as above. Immunoreactivity for CRMP2 and
NeuN was detected using an Alexa 488-labeled goat anti-
mouse IgG and an Alexa 546-labeled goat anti-rabbit fol-
lowing 90-minute incubation at RT. After washing with
0.1 M PBS as above, the sections were incubated for 5
minutes with 40, 6-diamidine-2-phenylindole dihy-
drochloride (DAPI), 1:10,000 (in 200 mL 0.01 M PBS, add
20 μL DAPI) (Roche Diagnostics, IN, USA) as a nuclear
stain. Labeling was imaged with a fluorescence microscope
(Axio Imager Z1 with Apotome, Zeiss, Germany). The
CRMP2-positive cells were examined in three different
regions: healthy, penumbra, and ischemic core in a coronal
section of the ipsilateral hemisphere (see Additional file 8:
Figure S6). To note, edema (swelling caused by a collec-
tion of fluid in the third space surrounding the tissue or
organ) was discernible, mostly at the 24 h time period,
and is therefore marked in the figure. To assess the spe-
cificity of the antibodies, negative control sections in
which the primary antibody is absent were prepared to
check for background staining levels. Immunostaining
were performed on sections obtained from the brains of
three mice in each group.
Results and discussion
Selection of PMCAO mice with neurological grades
between 1 and 2 and preparation of brain tissues for
grinding in liquid nitrogen
Mice exhibiting neurological deficiency 6 and 24 hours
after PMCAO were graded according to a routinely used
methodology in our laboratory [13,18]. Sixteen mice that
exhibited neurological grade (NG) 1 and 2 were used for
further experiments; two mice died, and one had NG 0
(no PMCAO) and one had NG 3 (extreme neurological
symptoms) (Additional file 1: Table S1). The selected
mice were decapitated and the brains were dissected on
ice. The ipsilateral (right hemisphere, non-injected) and
contralateral (left hemisphere; injected with saline or
PACAP38) hemispheres without the olfactory bulb (OB)
and cerebellum were quickly separated, placed in 2-mL
Eppendorf tubes, and deep frozen in liquid nitrogen fol-
lowed by storage at −80°C. Brains were ground to a very
fine powder in liquid nitrogen; aliquots of the finely
powdered tissue samples were stored at −80°C, and used
for extraction of total RNA or protein thus giving a com-
parative data expression analysis in the same sample.
Overview of the brain genomic response to PACAP38
injection in the ischemia brain (ipsilateral hemisphere)
by DNA microarray analysis
DNA microarray analysis and confirmatory RT-PCR
To investigate global changes in gene expression in the
ischemic hemisphere, the previously optimized protocols
for total RNA extraction, critical for any downstream
analysis, and DNA microarray analysis in mice were
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followed (Ogawa et al., 2011; [14,20]). The ischemic
hemisphere (ipsilateral) consists of the infarct core, pen-
umbra, and non-ischemic region (Additional file 8:
Figure S6). Thus, the present experimental design used
to perform the microarray analysis provides an overall
picture of the ischemic hemisphere rather than one
specific ischemic region. Nevertheless, and as will be dis-
cussed below, an additional experiment was carried out
to check for the expression of proteins in each of the
aforementioned regions in the ipsilateral hemisphere.
Prior to DNA microarray analysis, the expression of
GAPDH and β-actin, as positive controls, was confirmed
at both hemispheres at 6 and 24 h in the PMCAO sam-
ples, with or without PACAP; saline was used as control.
Results revealed the mRNAs for GAPDH and β-actin
were expressed almost uniformly across the tested con-
ditions (Figure 2).
DNA microarray analysis gave a wide change in gene
expressions as anticipated, and for confirmation of
alterations in gene expression by DNA microarray, we
randomly selected 14 upregulated genes and 6 downre-
gulated genes with annotated functions; one gene that
was the most highly upregulated at 6 h post-ischemia,
but with no known function, was also selected. Using
RT-PCR, the mRNA expression profiles are presented in
Figure 2, which validate the microarray experiment. Two
trends can immediately be observed in the upregulated
gene candidates examined, namely early (6 h) and late
(24 h) expression of target genes by PACAP38 treat-
ment. For example, the gamma-aminobutyric acid
(GABA) A receptor, subunit alpha 6, Gabra6, was found
to be strongly upregulated at 6 h in the PACAP-treated
ischemic hemisphere but was not expressed at 24 h. This





















































































































































































































































































































































































































































































































































































































































































































Figure 2 The mRNA expression profiles of differentially expressed genes. Both the upregulated and downregulated genes were selected
randomly. Gel images on top show the polymerase chain reaction (PCR) product bands stained with ethidium bromide; the band intensities are
also presented graphically below for clarity. Lane numbers 1 to 8 indicate sham control (lanes 1, 3, 5, and 7) and permanent middle cerebral
artery occlusion (PMCAO) treatment (lanes 2, 4, 6, and 8), respectively. P indicates pituitary adenylate cyclase-activating polypeptide (PACAP)
treatment; C is the control (minus PACAP). GAPDH and beta-actin genes were used a positive control. Semi-quantitative RT-PCR was performed as
described in Methods, and the specific 3’-UTR primers are detailed in Additional file 2: Table S2.
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report of Gabra6 regulation by PACAP. Why PACAP
affects Gabra6 gene expression is unclear, but it may be
related to GABA and glutamate levels, which, though
not been investigated in this study, are of future interest
for investigation. A gene with unknown function,
C030005H24Rik, showed the most increased mRNA ex-
pression fold at 6h, and we analyzed its expression by
design-specific primers based on the available gene se-
quence in the NCBI database. RT-PCR results revealed
only a slight increase in mRNA abundance at 6 h (Fig-
ure 2). However, as this gene still remains unannotated
and there are no functional domains identified so far, the
meaning of this gene expression under ischemia remains a
mystery. Interestingly, a gene neurofibromatosis 1 (Nf1),
which is known to regulate PACAP-mediated signaling in
astrocytes [25] was found to be slightly induced at 24 h.
Therefore, it would be tempting to speculate a role for
Gabra6 and Nf1 in PACAP-mediated neuroprotection.
Similarly, Il6, S100a5, Il22, Il1b, Igf1, and Ccl2 were
highly expressed at 6 h in the PACAP-treated ischemic
brain, whereas their expression level decreased at 24 h
compared to the PACAP effect alone (Figure 2). On the
other hand, Fgf21, Pitpnc1, and Epha3 genes showed an
increase in expression at 24 h (Figure 2). These results
suggest a clear demarcation in the expression of genes to
the administered PACAP38 with time, and that may be
linked to the progression of ischemia itself. However, fur-
ther detailed studies will be necessary to provide concrete
evidence for the hypothesis.
Here, we would like to emphasize an early first study
on neuroprotection by endogenous and exogenous
PACAP following stroke that was performed by the Lee
E Eiden’s group at the NIH (Bethesda, MD, USA). In
that study the cerebrocortical transcriptional response in
the MCAO model was studied in PACAP-deficient mice
and in wild-type mice using a 36K cDNA microarray
chip for transcriptome profiling of gene expression
changes in the cortex at 1 and 24 h post-ischemia [8]. A
large percentage of 142 up-regulated genes at 24 h were
shown to require endogenous PACAP, and the authors
suggest a more prominent role for PACAP in later re-
sponse to injury than in the initial response [8]. Al-
though 40 pmol of PACAP was used as an exogenous
treatment, compared to the 1 pmol used in our present
study, we looked at any similarities in gene expression
changes with our present data at both 6 and 24 h post-
ischemia (with or without PACAP). Only three upregu-
lated genes and one downregulated gene were found to
be common at 6 h, whereas two upregulated genes and
twenty-four downregulated genes were found to be com-
mon at 24 h by Chen et al. [8]. The lack of similarity be-
tween the Chen et al. [8] study and ours may lie in 1)
MCAO versus PMCAO and KO mice versus wild-type,
2) use of cDNA versus the whole genome microarray, and
3) different time points used (1 versus 6 h). Nevertheless,
we believe that as the two studies have identified unique
changes in gene expression, these data are complemen-
tary and represent the growing number of potential
PACAP-regulated gene transcripts in the ischemic
brain.
Tabulation of the differentially expressed genes
The next step was the analysis of the vast microarray
data (gene lists). As we had previously reported an in-
ventory of ischemia-related genes in the ipsilateral brain
hemisphere [14], we wanted to know at first how many
and what kind of genes PACAP alone influences in the
brain (ipsilateral hemisphere). Using the processed data
from the previous study [14] and this study on
changes in gene expression > 1.5-fold for upregulated
and < 0.75-fold for downregulated gene expression, at
both 6- and 24-h time points, we were able to list the
ischemia-related and PACAP-related genes. The first
two columns of Table 1 show the results of the com-
parison, and it is immediately clear that PACAP influ-
ences the expression of a lower number of genes (263
to 743; PACAP-related) genome-wide over the large
number of genes (622 to 2,759; ischemia-related)
showing changed expression under ischemia alone.
Interestingly, it was seen that the PACAP38 injection
influenced a greater number of gene expressions early,
that is, at 6 h post-ischemia, rather than at 24 h, sug-
gesting that PACAP indeed has a role in regulating
gene expression in the brain post-injection, a character
of the neuropeptide. We next asked how many genes
are influenced by PACAP under ischemia, and
Table 1 Changes in gene expression in the ipsilateral hemisphere revealed by comparison of genes expressed under
ischemia with or without pituitary adenylate cyclase-activating polypeptide (PACAP)-38 injection over saline control
Sampling time
(expression change)
Ischemia-related PACAP-related PACAP in
ischemia-related
Common: ischemia-related
and PACAP in ischemia-related
Common: PACAP-related and
PACAP in ischemia-related
6 h (upregulated) 1,237 435 839 171 43
6 h (downregulated) 622 743 498 31 24
24 h (upregulated) 2,759 263 831 49 30
24 h (downregulated) 2,104 271 1468 28 75
Results are presented as number of genes.
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Hori et al. Journal of Neuroinflammation 2012, 9:256 Page 10 of 18
http://www.jneuroinflammation.com/content/9/1/256
eliminating the ischemia alone-related genes, we could
narrow down our inventory to a considerably lower
number of genes (third column, Table 1). But this is
again a significantly high number of genes to discuss in
single study. Nonetheless, all these genes expression
data are open and freely available on the GEO website
at NCBI (GSE 28201 [14]; GSE 37565, this study) for
the scientific community.
To further narrow down our search, we also looked at
the common genes between two sets of data, that is,
ischemia-related and PACAP in ischemia-related (fourth
column, Table 1) and PACAP-related and PACAP in
ischemia-related (fifth column, Table 1). The gene num-
bers decreased drastically to 171 and 31 (upregulated
and downregulated at 6 h, respectively; Additional file 9:
Table S3), and 49 and 28 (upregulated and downregu-
lated at 24 h, respectively; Additional file 10: Table S4)
for the predominantly ischemic group, and to 43 and 24
(upregulated and downregulated at 6 h, respectively;
Additional file 11: Table S5), and 30 and 75 (upregulated
and downregulated at 24 h, respectively; Additional file
12: Table S6) for the predominantly PACAP group. For
details, see the genes listed in Additional files 9: Table
S3, 10: Table S4, 11: Table S5, 12: Table S6.
Functional categorization of differentially expressed genes
and candidate genes regulated by PACAP38 with potential
links to ischemic neuroprotection
To overcome the challenge of explaining the large gene
dataset, we also functionally categorized the obtained
gene lists (Additional files 13: Table S7, 14: Table S8, 15:
Table S9 16: Table S10; 6 and 24 h up/downregulation)
using the pathway- or specific disease states-focused
gene classifications available on the QIAGEN website
(SABiosciences; www.sabiosciences.com) in order to re-
veal the trend of predominant pathways affected by
PACAP in the ischemic hemisphere at 6 and 24 h post-
ischemia. Results show the distribution of genes among
multiple categories (Figures 3 and 4). At 6 h after
PACAP treatment, the number of upregulated gene
expressions is evident in contrast to the large number of
downregulated gene expression at 24 h. This indicates
that PACAP influences the regulation of numerous gene
pathways in the ischemic hemisphere quite early, and that
might have a role in neuroprotection. Based on the listing
of the gene candidates and their functional categorization,
we discuss potential PACAP-regulated genes, including a
novel gene in the context of a role for PACAP as a neuro-
protective peptide in limiting ischemia.
PACAP influences early regulation/induction of interleukins
The predominant gene with annotated function influ-
enced by PACAP38 injection was interleukin 6 (IL6; 4.3-
fold upregulated at 6 h; Additional file 9: Table S3) upon
analyzing the genes with focus on the keywords ischemia
and PACAP (fourth column, Table 1). By RT-PCR, the
IL6 mRNA abundance was also found to be strongly
increased under PACAP treatment at 6 h in the ischemic
hemisphere over both the sham and PMCAO alone ex-
pression levels (Figure 2). On the other hand, when fo-
cusing on the genes under the keywords PACAP and
ischemia (fifth column, Table 1), no interleukins were
found to be upregulated (Additional files 11: Table S5
and 12: Table S6). This is because in the ischemic hemi-
sphere at 24 h, the PACAP plus PMCAO expression
level was reduced compared to the sham plus PACAP
control. This suggests that interleukin is only one target
of PACAP action under ischemia, and PACAP might
regulate different gene sets at different stages of ische-
mia progression. In other words, the influence of
PACAP on interleukins should logically be early rather
than late, to see the neuroprotective effects of PACAP38
administration to the brain.
IL6 is one of the most well-known and critical inflam-
matory cytokines in the ischemic brain [26]. Further, this
result also re-confirms, and at the same time differenti-
ates, the finding of our previous study on ischemic brain
gene expression profiles [14], where IL6 was induced to
very high levels (10.35-fold and 89.23-fold upregulated
at 6 and 24 hours, respectively). It has been reported
that PACAP stimulates IL-6 expression from neurons
and astrocytes after ischemia [12], and the neuroprotec-
tive effect of PACAP mediates the IL-6 pathway [13].
This evidence supports our findings of increased IL6 ex-
pression in acute response after PACAP injection. Sur-
prisingly, the IL6 gene was not among the 49 common
genes at 24 h post-treatment, suggesting that PACAP
negatively influences IL6 expression after acute response.
IL6 seems to respond and rebound after the effects of
PACAP deficiency at 24 hours after injection. Using this
analytical approach, we can begin to see a certain func-
tion of PACAP38 in regulating the expression of the IL
inflammatory cytokines, namely, PACAP activates the
(See figure on previous page.)
Figure 3 Pathway and disease states-focused gene classification of pituitary adenylate cyclase-activating polypeptide
(PACAP)- influenced genes at 6 h post-ischemia. The up- and downregulated genes at 6 h hours after ischemia (ipsilateral hemisphere) were
classified based on the available categories of more than 100 biological pathways or specific disease states in the SABiosciences PCR array list
(QIAGEN; www.sabiosciences.com) for Mus musculus. The numbers in the y-axis represent the number of genes in each category, which are
indicated on the x-axis.
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differential and early induction of ILs during ischemia
progression.
Further, among the numerous cytokines found to be
induced in the ischemic hemisphere [14], only IL1b,
IL8rb, ILl1rap, and IL11 were found to be upregulated at
6, but not at 24 h (Additional files 9: Table S3 and 10:
Table S4). IL-11, a member of the IL-6 family of proin-
flammatory cytokines, can be a potential target for
PACAP-mediated neuroprotection. IL-11 also has a role
in the response to oxidative stress and compensatory
proliferation [27], and has recently been proposed as a
candidate cytokine clinically available for cardioprotec-
tion therapy [28,29]. Another potential target is the IL-1
receptor accessory protein gene IL1rap. The IL-1RAP is
a necessary part of the interleukin 1 receptor complex
that initiates signaling events to activate the IL-1-
responsive genes. Further, the IL1rap is also associated
with IL-1 beta (IL-1b), and an early study had revealed
that IL-1RAcP is necessary for centrally mediated neu-
roendocrine and immune responses to IL-1beta [30,31].
These reports imply that IL-11 and IL-1 pathway could
connect with PACAP-induced neuroprotection after
brain ischemia.
Novel induction of the cytotoxic and regulatory T cell
molecule (Crtam) gene at 6 h
We identified Crtam, also called the MHC class-1-
restricted T-cell-associated molecule, as a 4.2-fold upre-
gulated gene at only 6 h (Additional file 9: Table S3). To
our knowledge, this is the first report of Crtam gene
expression by PACAP. The Crtam gene was initially
identified as a new member of the immunoglobulin
superfamily (Ig-SF) from the molecular analysis of natural
killer T (NKT) cells, by Kennedy et al. [32]. CRTAM is
also expressed by other types of activated T cells, CD4+
and CD8+. Interestingly, CRTAM maintains the T cell’s
polarity, which regulates T cell activation and movement
through the lymphatic system and tissues [33]. Moreover,
CRTAM regulates IFN and IL-22 production [34]. In our
RT-PCR results, the IL22 mRNA expression was also
strongly upregulated in PACAP administration at 6 h
compared to the control (Figure 2), suggesting that
PACAP affects activation and invasion of T cells in the
ischemic brain. A recent review has stated that T lym-
phocytes are activated, infiltrated into the brain, and
appear to release cytokines to contribute to the early
inflammation and brain injury following an ischemic
stroke [35]. PACAP-induced neuroprotection may me-
diate T cell activation and infiltration to regulate the
acute phase of inflammation.
During the initial finding of this gene in lymphoid tis-
sues, the Crtam RNA was also found in the brain as
expected, but its significance has remained unclear [32].
In 2006, CRTAM was characterized and found to be
highly expressed in the human cerebellum, particularly
the Purkinje neurons, and where it was reported that
CRTAM/Necl-2 binding may contribute to neuronal
interactions [36]. Recently, the Crtam gene was also
reported as an ethanol-responsive gene, and associated
with alcohol preference in mice [37]. Although, we do
not know the neuronal CRTAM function, based on the
few reports available to date, it is tempting to speculate
a neuroprotective role under PACAP influence in the is-
chemic hemisphere. Moreover, as with the induction of
IL genes, it is of interest to note that Crtam is also regu-
lated by PACAP38 at 6 but not 24 h, suggesting that
PACAP effects at the molecular level can be seen within
hours of administration to the brain. This result is also
in accordance with our observation with the RT-PCR
data that the effect of PACAP on gene expression can be
divided into an early response (with potential involve-
ment in neuroprotection) and late response (secondary
effects) in the ischemic hemisphere. Nevertheless, add-
itional experiments by functional approaches using the
candidate genes are necessary to demonstrate the mech-
anism behind the action of PACAP.
Two-dimensional gel electrophoresis western blotting,
and immunofluorescent staining analysis identifies
CRMP2 as a candidate protein factor in PACAP-influenced
neuroprotection in the ischemic hemisphere
Total soluble protein profiles were first examined by
one-dimensional gel electrophoresis (SDS-PAGE). Staining
the separated proteins with Flamingo fluorescent stain
showed no significant differences in polypeptide patterns
among all the samples examined (Additional file 6: Figure
S4). Therefore, we proceeded to two-dimensional analysis.
Flamingo-stained two-dimensional gel protein spots clearly
revealed a major and newly appeared spot with a molecu-
lar weight of approximately 60 kDa and a pI of 5.5, in the
ischemic hemisphere at 6 h (lower left two-dimensional
gel image, Figure 5A) over the sham saline sample; this
spot was also observed in the PACAP38-treated ischemic
brain (lower right two-dimensional gel, Figure 5A) over
(See figure on previous page.)
Figure 4 Pathway and disease states-focused gene classification of pituitary adenylate cyclase-activating polypeptide
(PACAP)-influenced genes at 24 h post-ischemia. The up- and downregulated genes at 24 h hours after ischemia (ipsilateral hemisphere)
were classified based on the available categories of more than 100 biological pathways or specific disease states the same as mentioned in
Figure 3 in the SABiosciences PCR array list (QIAGEN; www.sabiosciences.com) for Mus musculus. The numbers in the y-axis represent the number
of genes in each category, which are indicated on the x-axis.
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Figure 5 Two-dimensional gel electrophoresis of the mouse brain. (A) Total protein in the Sham (control) and PMCAO (ischemic)
hemispheres were stained with Flamingo stain. (A) Separated proteins at 6 h after control and ischemia treatments, with (gels on right-hand side)
or without PACAP38 (gels on left-hand side), respectively. (B) Separated proteins in the same profile as above at 24 h. Newly appearing protein/s
in the ischemic hemispheres are indicated by the red dotted line circles, and the green dotted line circles represent the corresponding areas of
the saline and PACAP samples. Inset: enlarged circle protein profiles. Total protein extraction, separation, staining, and image analyses procedures
are detailed in Methods.
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the sham PACAP sample. Interestingly, the same spot was
also observed at a much stronger intensity (more than 2-
fold) in the ischemic hemisphere at 24 h (lower left two
dimensional gel image, Figure 5B) but not in the sham
saline sample. Two additional minor spots appeared at
approximately the same molecular weight range but with
a slightly acidic pI (isoelectric point). Surprisingly, and
in contrast to the 6 h results, the major and minor spots
were not found in the PACAP38-treated brain (lower
right two-dimensional gel image, Figure 5B) over the
sham PACAP sample. To identify the protein in these
newly appearing spots, we excised these three spots from
the stained gels and after in-gel trypsin digestion ana-
lyzed the peptides by MALDI-TOF-MS, as described in
Methods. The MASCOT search revealed the major
abundant protein to be a dihydropyrimidinase-related
protein 2 (DPYL2_MOUSE) or collapsin response medi-
ator protein 2 (CRMP2_MOUSE). No significant data
(protein IDs) could be obtained for the two protein spots
with the lowest abundance appearing exclusively at 24 h
post ischemia. The CRMP2 protein, as it more popularly
known, is involved in axonal growth and neuronal differ-
entiation [17]. Although there is no information to date
on the effects of PACAP on the CRMP2 protein, a few
studies have already shown that the CRMP2 protein is
induced in the brain after focal cerebral ischemia, in old
mouse brains, and in the cerebral cortex of rats [38-40].
We next examined by western blot analysis the
CRMP2 protein profile on SDS-PAGE. Using a specific
CRMP2 protein antibody three main bands of approxi-
mately 70, 65, and 63 kDa were detected (Figure 6). No
significant change in protein expression was seen among
the sham control and PMCAO samples, with or without
PACAP38 treatment. However, in the PMCAO samples
only, at an approximate molecular weight of 56 kDa, a
cross-reacting protein band was seen. At 6 h post-ische-
mia, the 56 kDa protein was increased in abundance
over the minus-PACAP sample. At 24 h post-PACAP
treatment the 56 kDa protein band was found at very
low levels. This result matches the induction profile of
the major protein spot seen on the two-dimensional gels.
Further, using two anti-phosphorylated CRMP2 proteins
antibodies, approximately 70 and 65 kDa and 70 kDa
cross-reacting bands were observed. However, no signifi-
cant change in abundance of protein bands was observed
(Additional file 17: Figure S7). No specific band at the 56
kDa molecular weight was seen in the PMCAO group.
These data rule out the possibility of protein phosphoryl-
ation as a post-translational modification for the appear-
ance of the 56 kDa cross-reacting protein band.
Immunofluorescent staining using anti-CRMP2 anti-
body revealed that the CRMP2 protein is localized to
the cytoplasm in neuronal cells as is evident from the
healthy region of the ipsilateral hemisphere (Figure 7).
Interestingly, in the penumbra, the CRMP2 protein
appears to be more abundant in the 6-h PACAP group.
In the core region, the CRMP2 protein is reduced in
abundance, in particular under PACAP38 treatment, es-
pecially prominent by almost no presence of CRMP2 at
24 h after PACAP treatment to the ischemic brain. Com-
paring these three data, it can be stated that 1) two-
dimensional gel electrophoresis and western blot analysis
confirmed the presence of a newly appearing 56 kDa pro-
tein, 2) PACAP treatment influences its induction at 6 h
post-treatment in the ischemic hemisphere, and 3) a very
low level of the CRMP2 protein on two-dimensional gel
at 24 h post-ischemia under PACAP treatment correlates
well with the results seen from western blot analysis data
and immunofluorescent staining of the core region. In
other words, our results show that PACAP treatment
affects the expression of CRMP2 protein, but how
PACAP and CRMP2 are involved in neuroprotection of
the brain remains to be answered.
Conclusions
To our knowledge the omics-based study demonstrates sig-
nificant change in gene and protein expressions after
PACAP38 injection in the ischemic brain. Results presented
in the study highlight the usefulness of global gene expres-
sion profiling in searching for changes in gene expression,
and delineating the molecular events in a defined experi-
mental PMCAO model. Furthermore, the proteomics ap-
proach proved to be critical in identifying the CRMP2
protein, which was surprisingly the most abundant and
12.5% ePAGEL (Anti-CRMP2 antibody)
(M)
Sham







Figure 6 Western blot analysis of the CRMP2 protein
cross-reacting proteins in sham control and permanent middle
cerebral artery occlusion (PMCAO) with or without pituitary
adenylate cyclase-activating polypeptide (PACAP) treatment.
Proteins cross-reacting with the anti-CRMP2 protein antibody are
visible as three constitutively present proteins (approximately 70, 65,
and 63 kDa size) in all samples. The approximately 56 kDa cross-
reacting protein is seen only in the ischemic hemisphere (PMCAO).
Lanes 1, 2 and 5, 6 are hemispheres dissected out at 6 h after
control and ischemia treatments respectively. The symbol – (minus)
indicates without PACAP38, that is, 1 μL of 0.9% saline, whereas +
(plus) indicates with 1 pmol (1 μL) of PACAP38 injection. Total
protein extraction, separation, Western blotting and image analyses
procedures are detailed in Methods. Total protein in the Sham
(control) and PMCAO (ischemic) hemispheres were stained with
Flamingo stain as shown in Additional file 6: Figure S4.
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newly appearing protein spot on the two-dimensional gel.
Post-confirmation of the two-dimensional gel spot by
MS and western blot analyses, immuno-double staining
revealed the possibility of CRMP2 as a controlling factor
in PACAP-regulated control of ischemic neuroprotec-
tion. Forward or reverse genetic approaches involving
certain target genes, including the most promising
candidate CRMP2 protein, will be necessary to increase
our understanding of the functional role of various genes
in response to an ischemic injury and to clarify the pre-
cise mechanism behind PACAP38-induced neuroprotec-
tion. Furthermore, to further enhance our understanding
of the functional roles of the many identified gene and














Neu N              CRMP2            Merge
Figure 7 Immunofluorescent staining. Neurons express CRMP2 at 6 and 24 h after permanent middle cerebral artery occlusion (PMCAO). A,B,C:
triple immunofluorescence staining for CRMP2, NeuN and 40, 6-diamidine-2-phenylindole dihydrochloride (DAPI); the merged picture displays
expression of CRMP2 by NeuN positive neuron but not DAPI-positive neurons. D,G,J,M,P: healthy; E,H,K,N,Q: penumbra; and F,I,L,O,R: core. D-R:
double immunofluorescence staining for CRMP2, and DAPI; the merged picture shows mutually exclusive expression of neuron. The merged
picture shows membranous localization of CRMP2 surrounding DAPI-positive nuclei. All images were captured in the ipsilateral hippocampus.
Intact (double): A, B, C; 6 h saline: D, E, F; 6-h pituitary adenylate cyclase-activating polypeptide (PACAP): G, H, I; 24 h saline: J, K, L; 24 h PACAP:
M, N, O; negative control: P, Q, R. Green - NeuN, Red - CRMP2, and Blue - DAPI. Scale bar: 20 μm. The sections were prepared as described in
Methods; see also Additional file 8: Figure S6.
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integrated pathway analysis (IPA) software for predicting
the possible pathways and underlying mechanisms of
PACAP-mediated molecular changes, and experiments,
especially with the PACAP knockout mice, will be essential.
Finally, the numerous specific PACAP target transcripts
that were unannotated have not been discussed here, and
will be also a target for future studies.
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